Humacyte is trading 9.92% down at $0.64 after second-quarter revenue and EPS missed expectations.
- Revenue was $0.41 million versus approximately $1.14 million expected; loss was $0.16 per share versus $0.10 expected.
- Phase 3 dialysis results were positive, and Humacyte plans a supplemental BLA filing.
- Symvess sales rose to $0.4 million from $0.1 million year over year.